DK2074123T3 - Nye anxiolytiske forbindelser - Google Patents

Nye anxiolytiske forbindelser

Info

Publication number: DK2074123T3
Authority: DK; Denmark
Prior art keywords: anxiolytic compounds; new anxiolytic; new; compounds; anxiolytic
Prior art date: 2006-10-16

Application number

DK07815371.5T

Other languages

English (en)

Inventor

Jonathan Bayldon Baell

Brad Sleebs

Ian Phillip Street

Nurul Quazi

Chinh Thien Bui

Bernard Luke Flynn

Original Assignee

Bionomics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-16

Filing date

2007-10-16

Publication date

2013-01-14

2007-10-16 Application filed by Bionomics Ltd filed Critical Bionomics Ltd

2013-01-14 Application granted granted Critical

2013-01-14 Publication of DK2074123T3 publication Critical patent/DK2074123T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK07815371.5T 2006-10-16 2007-10-16 Nye anxiolytiske forbindelser DK2074123T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US85198306P	2006-10-16	2006-10-16
PCT/AU2007/001566 WO2008046135A1 (en)	2006-10-16	2007-10-16	Novel anxiolytic compounds

Publications (1)

Publication Number	Publication Date
DK2074123T3 true DK2074123T3 (da)	2013-01-14

Family

ID=39313499

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07815371.5T DK2074123T3 (da)	2006-10-16	2007-10-16	Nye anxiolytiske forbindelser

Country Status (13)

Country	Link
US (7)	US8293737B2 (da)
EP (2)	EP2540722B1 (da)
JP (4)	JP5373613B2 (da)
AU (1)	AU2007312936B2 (da)
CA (2)	CA2954376C (da)
DK (1)	DK2074123T3 (da)
ES (1)	ES2399071T3 (da)
HK (1)	HK1132268A1 (da)
NZ (1)	NZ576036A (da)
PL (1)	PL2074123T3 (da)
PT (1)	PT2074123E (da)
SI (1)	SI2074123T1 (da)
WO (1)	WO2008046135A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2074123E (pt)	2006-10-16	2013-01-22	Bionomics Ltd	Novos compostos ansiolíticos
US10954231B2 (en)	2006-10-16	2021-03-23	Bionomics Limited	Anxiolytic compounds
WO2011031745A1 (en)	2009-09-09	2011-03-17	Achaogen, Inc.	Antibacterial fluoroquinolone analogs
CA2828780A1 (en)	2011-03-02	2012-09-07	Bionomics Limited	Novel small-molecules as therapeutics
US20140051701A1 (en) *	2011-03-02	2014-02-20	Bionomics Limited	Methods of treating a disease or condition of the central nervous system
AU2012253237B2 (en) *	2011-05-12	2015-09-24	Bionomics Limited	Methods for preparing naphthyridines
WO2014036595A1 (en) *	2012-09-04	2014-03-13	Bionomics Limited	Compounds and methods for treating diseases or conditions associated with the central nervous system and/or neurite outgrowth
AU2013204159B2 (en) *	2013-03-15	2015-05-07	Bionomics Limited	A Crystalline Form of an Anxiolytic Compound
JP2016510768A (ja) *	2013-03-15	2016-04-11	バイオノミックスリミテッド	抗不安化合物の塩、共結晶及び多形
WO2019109150A1 (en) *	2017-12-07	2019-06-13	Bionomics Limited	Methods of treating agitation
US20210355124A1 (en) *	2018-10-18	2021-11-18	Bionomics Limited	Cyclic compounds as receptor modulating therapeutics and methods and uses thereof
CN114585362B (zh) *	2019-09-23	2024-05-07	生态有限公司	治疗制剂及其用途
JP7570388B2 (ja)	2022-10-25	2024-10-21	株式会社熊平製作所	電気式施解錠装置及び開閉装置

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1022214A (en) *	1963-01-31	1966-03-09	Sterling Drug Inc	Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation
US3429887A (en)	1965-01-26	1969-02-25	Sterling Drug Inc	1,7-naphthyridine-3-carboxylic acid derivatives and their preparation
US3506668A (en) *	1965-01-26	1970-04-14	Sterling Drug Inc	Method of preparing 8-hydroxy-quinolines
JPS5023037B1 (da)	1970-12-29	1975-08-05
JPS5023036B1 (da)	1970-12-29	1975-08-05
JPS5023037A (da)	1973-07-03	1975-03-12
JPS5023036A (da) *	1973-07-06	1975-03-12
JPS5132594A (en) *	1974-09-11	1976-03-19	Kanebo Ltd	1 88 nafuchirijinjudotai no seiho
JPS5331690A (en) *	1976-09-01	1978-03-25	Shionogi & Co Ltd	Oxadithiacephalosporins
JPS54163596A (en) *	1978-06-09	1979-12-26	Daiichi Seiyaku Co	Flonaphlizine derivative
JPS55111486A (en) *	1979-02-19	1980-08-28	Dai Ichi Seiyaku Co Ltd	Preparation of pro 3,2,-b -1,8-naphthyridine derivative
JPS55151584A (en) *	1979-05-11	1980-11-26	Dai Ichi Seiyaku Co Ltd	Preparation of 1,8-naphthyridine derivative
JPS56115787A (en) *	1980-02-19	1981-09-11	Dai Ichi Seiyaku Co Ltd	Preparation of furo (3,2-b)(1,8)naphthyridine derivative
JPS56118083A (en) *	1980-02-22	1981-09-16	Dai Ichi Seiyaku Co Ltd	Furo(3,2-b)(1,8)naphthyridine derivative
JPS56118081A (en) *	1980-02-22	1981-09-16	Dai Ichi Seiyaku Co Ltd	Preparation of 6-methoxy-1,8-naphthyridine
JPS5726688A (en)	1980-07-24	1982-02-12	Dai Ichi Seiyaku Co Ltd	Furo 3,2-b 1,8-naphthyridine-7-carboxylic acid derivative
JPS57109790A (en) *	1980-12-26	1982-07-08	Dai Ichi Seiyaku Co Ltd	Furo(3,2-b)1,8-naphthyridine-7-carboxylic acid derivative
US4404201A (en) *	1981-11-13	1983-09-13	Warner-Lambert Company	Cephalosporins
JPS5993080A (ja) *	1982-11-18	1984-05-29	Sumitomo Chem Co Ltd	１，５−ナフチリジンカルボン酸誘導体
DE68919273T2 (de) *	1988-05-10	1995-03-23	Ici Pharma	Cephalosporine, Verfahren zu ihrer Herstellung und pharmazeutische Präparate.
US5095015A (en)	1990-07-24	1992-03-10	Neurogen Corporation	Certain azacycloalkyl imidazopyrimidines; a new class of gaba brain receptor ligands
US5182290A (en)	1991-08-27	1993-01-26	Neurogen Corporation	Certain oxazoloquinolinones; a new class of GABA brain receptor ligands
US5182386A (en)	1991-08-27	1993-01-26	Neurogen Corporation	Certain imidazoquinoxalinones; a new class of gaba brain receptor ligands
IT1251202B (it) *	1991-09-13	1995-05-04	Mediolanum Farmaceutici Spa	6-amminochinoloni, sintesi ed impiego come antibatterici
US5212310A (en)	1991-12-19	1993-05-18	Neurogen Corporation	Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5306819A (en)	1992-08-27	1994-04-26	Neurogen Corporation	Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
US5750702A (en)	1993-10-27	1998-05-12	Neurogen Corporation	Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands
US5484944A (en)	1993-10-27	1996-01-16	Neurogen Corporation	Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
US6211365B1 (en)	1996-01-19	2001-04-03	Neurogen Corporation	Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
US5804686A (en)	1996-01-19	1998-09-08	Neurogen Corporation	fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
US6013650A (en)	1996-03-14	2000-01-11	Neurogen Corporation	Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
AU2218997A (en)	1996-03-22	1997-10-10	Neurogen Corporation	Certain fused pyrrolecarboxamides as gaba brain receptor ligands
US5723462A (en)	1996-04-26	1998-03-03	Neurogen Corporation	Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
HUP0003258A3 (en) *	1997-08-25	2001-05-28	Neurogen Corp Branford	Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
US6143760A (en)	1997-08-25	2000-11-07	Neurogen Corporation	Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands
AU2793199A (en)	1998-02-26	1999-09-15	Neurogen Corporation	2-(het-)aryl-4-(cyclic amino substituted) heteroaryl fused pyridine derivatives,their preparation and their use as (ant-)agonists for gaba (a) brain receptors
DE19826050A1 (de)	1998-06-12	1999-12-16	Bayer Ag	Verfahren zur Herstellung von Chinolon- und Naphthyridoncarbonsäuren und deren Ester
US6177569B1 (en)	1998-08-25	2001-01-23	Neurogen Corporation	Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands
WO2000037471A1 (en)	1998-12-23	2000-06-29	Neurogen Corporation	2-amino-9-alkylpurines: gaba brain receptor ligands
CA2371472A1 (en)	1999-05-06	2000-11-16	Neurogen Corporation	Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
US6297256B1 (en)	1999-06-15	2001-10-02	Neurogen Corporation	Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands
CA2388593A1 (en)	1999-11-12	2001-05-17	Neurogen Corporation	Bicyclic and tricyclic heteroaromatic compounds
WO2001092257A1 (en)	2000-05-26	2001-12-06	Neurogen Corporation	Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands
AU2001273639A1 (en)	2000-06-26	2002-01-08	Neurogen Corporation	Aryl fused substituted 4-oxy-pyridines
US6423956B1 (en)	2000-07-28	2002-07-23	Optical Biopsy Technologies	Fiber-coupled, high-speed, integrated, angled-dual-axis confocal scanning microscopes employing vertical cross-section scanning
JP2004506038A (ja)	2000-08-16	2004-02-26	ニューロゲン　コーポレイション	２，４−置換ピリジン誘導体
MXPA03001945A (es)	2000-09-06	2003-09-10	Neurogen Corp	Tetrahidroindazoles sustituidos con arilo y su uso como ligandos para el receptor gaba-a.
US20020151591A1 (en)	2000-10-17	2002-10-17	Anabella Villalobos	Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
AUPR283801A0 (en)	2001-02-01	2001-03-01	Australian National University, The	Chemical compounds and methods
EP1363606A1 (en)	2001-03-01	2003-11-26	Pfizer Products Inc.	Use of gaba[a] inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators or vitamin e for the treatment of coginitive disorders
MXPA03008681A (es)	2001-03-27	2004-04-02	Neurogen Corp	(oxo-pirazol[1,5]pirimidin-2-il)alquil-carboxamidas.
US7084156B2 (en)	2001-11-27	2006-08-01	Merck & Co., Inc.	2-Aminoquinoline compounds
AU2002352868A1 (en)	2001-11-27	2003-06-10	Merck & Co., Inc.	4-aminoquinoline compounds
CN1652784A (zh)	2002-05-14	2005-08-10	加利福尼亚大学董事会	取代的喹诺酮羧酸、它们的衍生物、作用部位、以及其用途
IS7839A (is)	2002-11-22	2004-05-23	Merck Frosst Canada Ltd.	4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
US7829694B2 (en)	2002-11-26	2010-11-09	Medtronic, Inc.	Treatment of neurodegenerative disease through intracranial delivery of siRNA
TW200427688A (en) *	2002-12-18	2004-12-16	Glaxo Group Ltd	Antibacterial agents
TW200418835A (en)	2003-01-24	2004-10-01	Tanabe Seiyaku Co	A pyrazolopyrimidine compound and a process for preparing the same
JP2005162726A (ja) *	2003-01-24	2005-06-23	Tanabe Seiyaku Co Ltd	ピラゾロピリミジン化合物およびその製法
US20050031652A1 (en)	2003-02-25	2005-02-10	Allergan, Inc.	Compositions and methods comprising memantine and polyanionic polymers
CA2518443A1 (en) *	2003-03-12	2004-09-30	Abbott Laboratories	Naphthyridine derivatives as antibacterial agents
DE102004004971B3 (de) *	2004-01-31	2005-09-15	Aventis Pharma Deutschland Gmbh	Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
US7402674B2 (en)	2004-01-31	2008-07-22	Sanofi-Aventis Deutschland Gmbh,	7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7498341B2 (en)	2004-01-31	2009-03-03	Sanofi Aventis Deutschland Gmbh	Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
ATE438645T1 (de) *	2004-01-31	2009-08-15	Sanofi Aventis Deutschland	7-phenylamino-4-chinolon-3-carbonsäure-derivate verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE102004004972B3 (de)	2004-01-31	2005-09-15	Aventis Pharma Deutschland Gmbh	Heterocyclisch substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7470706B2 (en)	2004-01-31	2008-12-30	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
PE20060285A1 (es)	2004-03-30	2006-05-08	Aventis Pharma Inc	Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
CN101068788A (zh)	2004-11-01	2007-11-07	弗·哈夫曼-拉罗切有限公司	作为gabab受体的别构增强剂的喹啉化合物
US20070293492A1 (en)	2004-12-03	2007-12-20	Devita Robert J	Quinoline Tachykinin Receptor Antagonists
MX2007014929A (es)	2005-06-02	2008-02-15	Hoffmann La Roche	3-metansulfonilquinolinas como mejoradores de gaba-b.
ES2392181T3 (es)	2005-09-29	2012-12-05	Sanofi	Derivados de fenil-[1,2,4]-oxadiazol-5-ona con grupo fenilo, procesos para su preparación y su uso como productos farmacéuticos
US20080044390A1 (en)	2006-08-11	2008-02-21	Xiaowei Jin	Methods and compositions for the treatment of neurodegenerative disorders
PT2074123E (pt)	2006-10-16	2013-01-22	Bionomics Ltd	Novos compostos ansiolíticos
AR076687A1 (es)	2009-05-18	2011-06-29	Infinity Pharmaceuticals Inc	Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen
DK2672823T3 (da)	2011-02-07	2016-11-28	Biogen Ma Inc	S1p-modulerende midler
CA2828780A1 (en)	2011-03-02	2012-09-07	Bionomics Limited	Novel small-molecules as therapeutics
US20140051701A1 (en)	2011-03-02	2014-02-20	Bionomics Limited	Methods of treating a disease or condition of the central nervous system
AU2012253237B2 (en)	2011-05-12	2015-09-24	Bionomics Limited	Methods for preparing naphthyridines

2007
- 2007-10-16 PT PT78153715T patent/PT2074123E/pt unknown
- 2007-10-16 JP JP2009531697A patent/JP5373613B2/ja active Active
- 2007-10-16 AU AU2007312936A patent/AU2007312936B2/en active Active
- 2007-10-16 CA CA2954376A patent/CA2954376C/en active Active
- 2007-10-16 EP EP12186384.9A patent/EP2540722B1/en active Active
- 2007-10-16 ES ES07815371T patent/ES2399071T3/es active Active
- 2007-10-16 CA CA2666219A patent/CA2666219C/en active Active
- 2007-10-16 US US12/311,872 patent/US8293737B2/en active Active
- 2007-10-16 WO PCT/AU2007/001566 patent/WO2008046135A1/en active Application Filing
- 2007-10-16 EP EP07815371A patent/EP2074123B1/en active Active
- 2007-10-16 NZ NZ576036A patent/NZ576036A/en not_active IP Right Cessation
- 2007-10-16 PL PL07815371T patent/PL2074123T3/pl unknown
- 2007-10-16 SI SI200731109T patent/SI2074123T1/sl unknown
- 2007-10-16 DK DK07815371.5T patent/DK2074123T3/da active
2009
- 2009-12-15 HK HK09111778.6A patent/HK1132268A1/xx unknown
2012
- 2012-09-14 US US13/617,153 patent/US8551990B2/en active Active
- 2012-09-14 US US13/617,317 patent/US8614212B2/en active Active
2013
- 2013-05-20 JP JP2013106650A patent/JP5739476B2/ja active Active
- 2013-09-18 US US14/030,808 patent/US8906912B2/en active Active
2014
- 2014-11-05 US US14/533,808 patent/US9573945B2/en active Active
2015
- 2015-04-23 JP JP2015088672A patent/JP6138191B2/ja active Active
2017
- 2017-01-04 US US15/398,472 patent/US9975892B2/en active Active
- 2017-02-08 JP JP2017021529A patent/JP6506322B2/ja active Active
- 2017-12-15 US US15/844,295 patent/US10233181B2/en active Active

Also Published As

Publication number	Publication date
EP2074123B1 (en)	2012-12-05
JP2010506829A (ja)	2010-03-04
JP2013189453A (ja)	2013-09-26
EP2540722B1 (en)	2016-06-08
JP2015155444A (ja)	2015-08-27
SI2074123T1 (sl)	2013-03-29
JP5739476B2 (ja)	2015-06-24
PL2074123T3 (pl)	2013-04-30
US9975892B2 (en)	2018-05-22
AU2007312936B2 (en)	2013-09-26
WO2008046135A1 (en)	2008-04-24
US20130012508A1 (en)	2013-01-10
US20180105524A1 (en)	2018-04-19
US20170183347A1 (en)	2017-06-29
US8906912B2 (en)	2014-12-09
US9573945B2 (en)	2017-02-21
US8614212B2 (en)	2013-12-24
NZ576036A (en)	2010-10-29
CA2666219C (en)	2017-02-07
PT2074123E (pt)	2013-01-22
US10233181B2 (en)	2019-03-19
EP2074123A1 (en)	2009-07-01
US8551990B2 (en)	2013-10-08
ES2399071T3 (es)	2013-03-25
US20150166534A1 (en)	2015-06-18
JP2017105818A (ja)	2017-06-15
EP2540722A1 (en)	2013-01-02
JP5373613B2 (ja)	2013-12-18
EP2074123A4 (en)	2011-09-07
JP6138191B2 (ja)	2017-05-31
CA2954376A1 (en)	2008-04-24
CA2666219A1 (en)	2008-04-24
AU2007312936A1 (en)	2008-04-24
US20140045839A1 (en)	2014-02-13
US20100105678A1 (en)	2010-04-29
JP6506322B2 (ja)	2019-04-24
HK1132268A1 (en)	2010-02-19
US8293737B2 (en)	2012-10-23
CA2954376C (en)	2019-06-11
US20130012509A1 (en)	2013-01-10

Publication	Publication Date	Title
LTPA2020501I1 (lt)	2020-02-10	Pakeistieji enaminokarbonilo junginiai
DK2074123T3 (da)	2013-01-14	Nye anxiolytiske forbindelser
CY2017016I2 (el)	2017-07-12	Αναστολεις πρωτεασωματος
DK2185567T3 (da)	2011-05-16	Substituerede bicyclolactam-forbindelser
EP2170076A4 (en)	2011-09-07	4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS
DK2061766T3 (da)	2010-12-13	Nye forbindelser
BRPI0813500A2 (pt)	2015-01-06	Compostos antivirais
BRPI0821086A2 (pt)	2014-10-07	Compostos inseticidas
ATE510825T1 (de)	2011-06-15	Acylaminopyrazole als fgfr-inhibitoren
ATE542825T1 (de)	2012-02-15	Substituierte piperidino-dihydrothienopyrimidine
ATE524477T1 (de)	2011-09-15	Aziridinylepothilonverbindungen
DK2086960T3 (da)	2014-06-10	Nye inhibitorer af glutaminylcyclase.
BRPI0815042A2 (pt)	2015-02-10	Compostos de pirazol
DE602008003015D1 (de)	2010-11-25	Heterocyclische spiroverbindungen
EP2079466A4 (en)	2011-09-07	SUBSTITUTED INDOLE COMPOUNDS
ATE480545T1 (de)	2010-09-15	Imidazo-verbindungen
BRPI0811264A2 (pt)	2014-11-04	Compostos
SMT201600045B (it)	2016-02-25	Composti tetraciclinici c7-fluoro sostituiti
ATE506358T1 (de)	2011-05-15	2-benzylpyridazinonderivate als met-kinasehemmer
EP1985620A4 (en)	2012-08-15	COMPOUND 10a-AZALIDE
DK2120936T3 (da)	2011-09-26	Nye fremgangsmåder
DK2234976T3 (da)	2013-06-24	Nye pyrazol-substituerede arylamider
BRPI0814424A2 (pt)	2015-01-06	Compostos heterociclila
BRPI0720224A2 (pt)	2013-12-24	Arilpirazóis substituídos
BRPI0809996A2 (pt)	2014-10-14	Compostos